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Abstract: Tamoxifen is a nonsteroidal antiestrogen that is currently and widely used in the treatment of breast cancer in all of its stages, in adjuvant 
therapy as a long-term suppressant of tumor recurrence and also as a chemopreventive agent in women that are in high risk of developing this type of 
estrogen-dependent cancer. 
From a toxicological and (bio)analytical point of view the knowledge of the metabolic pathways of a drug is found to be extremely im- portant. So, 
in the present work the most important tamoxifen biotransformation steps were reviewed in the light of recent pharmacologi- cal data. This overview 
also includes the current controversy concerning tamoxifen DNA-damaging (genotoxic) versus non-genotoxic mechanisms. 
A special focus will be given to the putative application of electrochemical methods as a modern and reliable analytical tool for determi- nation of 
tamoxifen and its metabolites. Moreover, the potential of DNA electrochemical sensors for detection of structural damage to DNA as a basis for 
toxicity screening is highlighted. 
Future prospects looking for the importance of developing new analytical methodologies are also discussed. 
Keywords: Biotransformation, breast cancer, DNA, electrochemistry, sensor, Tamoxifen. 
 
INTRODUCTION 
Selective estrogen receptor modulators (SERMs), known previ- 
ously as “antiestrogens”, are therapeutic agents used for the preven- 
tion and treatment of several diseases such  as osteoporosis and 
breast cancer. Currently, there are two classes of clinically ap- 
proved SERMs the triphenylethylene (e.g., tamoxifen) and the ben- 
zothiophene derivatives (e.g., raloxifene) [1-3]. Despite the devel- 
opment of newer SERMs, namely toremifene, tamoxifen still re- 
mains the SERM of first choice for the treatment of hormone- 
responsive breast cancer. 
Tamoxifen (TAM, Fig. 1), [Z-1-[4-(2-dimethylamino)ethoxy] 
phenyl-1,2-diphenylbut-1-ene], the class representative of triphen- 
ylethylenes, is a SERM that has been used for nearly three decades 
as an adjuvant and/or chemotherapeutic agent for the treatment of 
all stages of hormone-dependent breast cancer [4-6]. 
Tamoxifen has the greatest therapeutic effect on estrogen recep- 
tor (ER) positive tumors, but women with both estrogen receptor 
positive and negative tumors show an objective remission rate of up 
to 30% and an improved life expectancy [3, 5, 6]. 
TAM was first used in 1971 as an antineoplastic and was ap- 
proved for use by the Food and Drug Administration (FDA) in 1977 
for the treatment of advanced breast cancer in women. In 1985, 
FDA approved the use of tamoxifen as an adjuvant therapy in 
postmenopausal women with node-positive breast cancer, and in 
1986, approval was obtained for its use alone. In 1989, the use of 
tamoxifen in the treatment of premenopausal women with ER- 
positive advanced breast cancer was approved by FDA. In 1990, an 
indication as an adjuvant was approved for pre and postmenopausal 
patients who had node-positive ER-positive breast cancer. In 1993, 
the same agency approved the indication for tamoxifen use in the 
treatment of advanced breast cancer in men [4, 7-10]. 
More recently, data from a large-scale clinical trial in the 
United States have shown that the administration of tamoxifen 
to women at a high risk of developing the disease resulted in a 
50% reduction in the occurrence of invasive breast cancer [11]. 
This observation has prompted the US FDA to approve tamoxifen 
use as a prophylactic breast cancer agent in high-risk women. 
The optimum duration of the tamoxifen treatment has not been 
clearly established, but the data so far collected suggest that a 2 
year period is not sufficient and at least 5 years are required to be 
beneficial. In fact tamoxifen administration for 5 years is believed 
to reduce the risk of recurrence of breast cancer both locally and 
systemically [10-12]. 
In addition to antitumour activity, tamoxifen exerts beneficial 
effects on osteoporosis as shown by clinical trials on long-term 
treatment of postmenopausal women. It is also described that ta- 
moxifen reduces the incidence of cardiovascular diseases and low- 
ers circulating serum cholesterol [4, 13]. 
TAMOXIFEN MECHANISM OF ACTION 
Breast cancer was first recognized to be an estrogen-dependent 
disease being 75% of breast cancers positive for ER. The stimula- 
tion of estrogen receptor by estradiol is often associated with the 
development of breast cancer and in turn one of the principal treat- 
ment strategies involves estrogen withdrawal [3-5]. As a selective 
estrogen receptor modulator tamoxifen competes with estrogen for 
binding to the estrogen receptor and therefore inhibits tumor growth 
by interfering with the survival and proliferative signals regulated 
by estrogen [6]. Tamoxifen can act either as an estrogen-antagonist 
or as an estrogen-agonist depending on the tissue in which operates 
[4, 6]. 
In breast tissue, tamoxifen mainly act as an estrogen antagonist 
stopping or reducing estrogen dependent cancer cell proliferation 
even though it can operate as an estrogen agonist on other parts of 
the body. In fact, in postmenopausal women tamoxifen exerts es- 
trogenic activity in the endometrium, vaginal epithelium, bone and 
 
 
 
 
 
 
 
Fig. (1). Tamoxifen (TAM) and its main phase I metabolites. 
 
on serum lipids [3, 4, 6]. The overall benefits of the described activ- 
ity are connected with protective effects against cardiovascular 
disease and osteoporosis in breast cancer patients [5]. 
In addition it was also described a tamoxifen binding effect to 
the microsomal antiestrogen binding site, interaction with protein 
kinase C, calmodulin-dependent enzymes and acyl coenzyme A: 
cholesterol acyl transferase. It is believed that each of these ta- 
moxifen targets might explain some of its genomic as well as non- 
genomic effects [8-10]. 
In summary, one can assume that tamoxifen mechanism is still 
a complex subject matter, being its action both species and tissue 
specific, and potentially dependent on the duration of use. Accord- 
ingly, the current breast cancer therapeutic strategy involves the 
blocking of the estrogen action on tumor cells via different ap- 
proaches: a) preventing the binding of estrogen to its receptor by 
using an antiestrogen compound; b) preventing the biosynthesis of 
estrogen through the use of aromatase inhibitor; or c) down- 
regulating estrogen receptor protein levels using a pure antiestrogen 
[9, 10]. 
 
BENEFITS VS RISKS OF TAMOXIFEN 
Because of tamoxifen pro-estrogenic action on other target 
tissue sites, its use is often associated with various beneficial ef- 
fects. In fact it appears to maintain or restore bone mineral density 
and reduce cholesterol levels in women being treated for breast 
cancer [5, 10-13]. 
Despite tamoxifen therapeutic value, several adverse effects 
have been recognized related with its use, either as a chemothera- 
peutic or as a chemopreventive agent, against breast cancer. Among 
them, the development of uterine and endometrial cancer and ve- 
nous thrombotic events are the most critical. A serious limitation of 
tamoxifen therapy is the inevitable appearance of resistance, which 
occur either de novo or is acquired after several months of treatment 
[4, 6, 12, 13]. Tamoxifen resistance is considered to be related with 
interindividual variability and genetic factors [11-15]. 
All the above mentioned aspects are up-and-coming topics on 
this area and give reason for the need to further explore the poten- 
tial carcinogenic mechanisms of tamoxifen. 
TAMOXIFEN METABOLISM 
Although the adverse effects of tamoxifen have been attributed 
to its hormonal properties, there is currently a deep interest in the 
study of TAM biotransformation and identification of metabolites 
since they could act as chemical carcinogens. 
After oral administration, TAM is extensively metabolized by 
phase I and phase II enzymes into several types of metabolites. In 
women several phase I TAM metabolites have been characterized, 
mainly obtained by N-demethylation, N-oxidation, epoxidation, 
hydroxylation and isomerization bioactivation reactions (N- 
demTAM, AminoTAM, TAM N-oxide, EpoxiTAM, 4-OHTAM, 4- 
OH-N-demTAM,   -OHTAM and E-4-OHTAM) (Fig. 1) [2, 3, 8]. 
Demethylation of the aminoethoxy side chain to N-demTAM ap- 
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pears to be the main route of TAM metabolism [4, 16, 17]. The 
progressive demethylation of the TAM side chain first to N- 
demTAM, the principal metabolite in humans, and then to Amino- 
TAM does not affect the biological action of tamoxifen [17]. 
A variety of cytochrome P450 isoforms have been already 
shown to be involved in phase I metabolic pathways. Recently, it 
was demonstrated that in humans the 4-hydroxylation of TAM is 
primarily catalyzed by the hepatic CYP2D6 while the N- 
demethylation process is catalyzed by  CYP3A (Fig. 2) [17]. 4- 
OHTAM metabolite has been shown to possess a high affinity for 
ERs and more potency than TAM in suppressing estrogen- 
dependent cell proliferation. It has been also shown that 4-OH-N- 
demTAM (also known as endoxifen) have a potency similar to 4- 
OHTAM with respect to ER binding affinity, suppression of estro- 
gen-dependent cell growth, and gene expression [4]. Since the 
plasma concentration of this metabolite in breast cancer patients has 
been reported to be much higher (over 6-fold) than that of TAM it 
is believed that it can play also an important role in vivo [16, 17]. 
The formation of various -OHTAM metabolites, obtained by 
hydroxylation of the -carbon, derived from phase I metabolites (  - 
OHTAM, Fig. 3) has been also reported [11, 18]. These compounds 
were detected at low concentrations in the plasma of women receiv- 
ing tamoxifen therapy. -OHTAM N-oxide and -OH-N-demTAM 
have also been identified as metabolites in a rat liver microsomal 
system and in the urine of breast cancer patients treated with the 
drug. All the mentioned  -OHTAM metabolites has been reported 
to be a substrate of hydroxysteroid(alcohol) sulfotransferases, en- 
zymes involved in its subsequent activation, even though this step 
has not been systematically studied [4]. Human phenol-sulfating 
and estrogen sulfotransferases have been proposed as the major 
enzymes involved in the sulfation of 4-OHTAM [18, 19]. 
Tamoxifen metabolism has been shown to generate, either 
chemically or enzymatically, at least three different electrophilic 
metabolites that include a carbocation, a quinone methide and o- 
quinone (Fig. 4) [11, 16]. These highly reactive species can undergo 
subsequent processes of polymerization with themselves  and/or 
with biomacromolecules and endogenous antioxidants (Fig. 5 and 
Fig. 6) [20, 22]. The o-quinone resulting from oxidation of the 
catechol metabolite, 3,4-diOHTAM, can alkylate amino acid resi- 
dues on proteins, even though the functional significance of the 
binding of active metabolites of tamoxifen to proteins is still un- 
clear. The o-quinone can cause damage to cellular DNA through 
generation of reactive oxygen species, and/or alkylation of DNA [4, 
21-23]. There is now good evidence that -OHTAM plays an im- 
portant role in the formation of the electrophilic species responsible 
for tamoxifen-mediated DNA and protein damage (Fig. 1 and Fig. 
7). The carbocation species can undergo a facile rotation around the 
central double bond and therefore TAM-DNA adducts can exist, 
due to  the potential for isomerization, as four diastereoisomers. 
Nevertheless the E forms of these adducts predominate [20-23]. 
Scarce studies have addressed this topic and consequently many 
conjugates/adducts were never detected in biological fluids because 
they have never been specifically looked for yet. 
It has been previously shown that   -hydroxytamoxifen undergo 
a phase II pathway and is excreted as -OHTAM-O-glucuronide, 
catalyzed by glycosyltransferases (uridine 5'-diphospho-glucurono- 
syltransferase, UDP-glucuronosyltransferase, UGT), in what is 
considered a detoxification route. TAM-glucuronide conjugates 
have been at present identified in the urine, serum, and bile of 
TAM-treated breast cancer patients [24]. 
Clinical studies suggest that the plasma concentrations of TAM 
and its metabolites vary widely among patients. It is likely that 
variable activity of the enzymes involved alter the pattern of me- 
tabolism of TAM, leading to differences in systemic exposure of 
TAM and/or one or more of its active metabolites [4, 11, 16, 18]. 
TAMOXIFEN METABOLISM: IS THIS ISSUE AN ANSWER 
FOR TAM BENEFITS VS RISKS? 
The mechanisms underlying the variable response to tamoxifen 
have been the subject of intense study but remain obscure yet. It is 
consensual the idea that tamoxifen side effects may be related to the 
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Fig. (2). Enzymatic systems engaged in the formation of the most active metabolites of tamoxifen. 
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Fig. (3). Formation of  -hydroxylated tamoxifen metabolites. 
 
different patterns of metabolism. Really, the compelling evidence 
that tamoxifen is converted to antiestrogenic metabolites, that are 
more potent than TAM itself, generated one of the foremost ex- 
planatory hypothesis in which TAM metabolism is considered to be 
the major contribute to the interindividual variability found in clini- 
cal data [4, 5, 16]. Recent research on tamoxifen has shown that 
potentially a number of women with breast cancer may not receive 
the benefit from taking tamoxifen, because of their unique genetic 
make-up since they have a special version of a CYP enzyme 
(CYP2D6, commonly referred as 2D6) [25]. This enzyme may 
reduce the effectiveness of tamoxifen and increase the chance of 
breast cancer recurrence (Fig. 2). 
On the other hand it is also believed that the cellular mechanism 
underlying TAM-induced carcinogenesis may be related to its par- 
tial estrogenic effect through the estrogen receptors and/or geno- 
toxic damage induced by electrophilic metabolites. In fact, the 
metabolic activation of the drug, mainly done by the CYP3A family 
(Fig. 2 and Fig. 4), generates electrophilic species, with subsequent 
formation of reactive electrophilic quinines, that can interact with 
DNA causing damage and subsequently gene mutations (Fig. 5 and 
Fig. 6) [26]. However it is still controversial whether that DNA 
damage and the formation of TAM-DNA adducts occurs in human 
uterine tissues, and there is no evidence that this can be causally 
related to the mechanisms of carcinogenesis [5, 15]. Controversy 
still remains as to whether the metabolic activation result in geno- 
toxicity or whether a non-genotoxic mechanism is responsible for 
the associated elevations in human endometrial carcinoma risk. 
ELECTROCHEMICAL OUTLOOK 
 
General 
In drug discovery process, one crucial task is the elucidation the 
metabolic fate of a drug candidate in the human body [27-29]. The 
increasing number of new chemical entities derived in recent years 
requires fast screening techniques that provide both reliable and 
easily accessible information about the biotransformation. For eco- 
nomic reasons it is important to perform, these tests at an early 
stage to exclude unsuitable drug candidates. Therefore, several 
chemical and enzymatic model systems have been developed that 
mimic metabolic processes in vitro in order to perform a satisfac- 
tory simulation of the situation in vivo [30-32]. 
Electrochemistry is one of the most sensitive and versatile tech- 
niques available for the study of biomolecules [33, 34]. The use of 
electrochemical techniques for the determination of compounds of 
pharmaceutical interest in different matrices is continually gaining 
in importance. The inherent sensitivity and high selectivity of the 
techniques allow very simple determinations, both in commercial 
samples and in body fluids in the presence of metabolites or impuri- 
ties such as precursors used in the synthesis of the compounds [35- 
37]. 
Electrochemical methods are nowadays considered to be useful 
tools for the investigation of electron-transfer reactions and can be 
used for simulations of biological (i.e. metabolic) redox reactions 
[38-42]. In fact, a major bottleneck in metabolic profiling remains 
in the detection and identification of active metabolites in complex 
mixtures. As electrochemistry is often used for the determination of 
oxidation mechanisms, it can be applied as a simulation technique 
in drug metabolism studies [31, 43]. In fact, metabolically active 
sites, i.e., positions at which the drug is prone to oxidation, can thus 
be rapidly elucidated and possible metabolites can be directly iden- 
tified. 
First achievements in the use of electrochemistry as a tool for 
simulating the oxidative metabolism of drugs date back to the early 
1980s. At that time, mechanistic comparisons between electro- 
chemical and enzymatic oxidation reactions were of huge interest. 
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Fig. (4). Electrophilic species generated on tamoxifen metabolism. 
 
In fact, the data on the redox properties of drugs and biomolecules 
might have a profound effect to understand their in vivo redox be- 
haviour or pharmaceutical activity. Accordingly, different electro- 
chemical studies have been addressed to mimic phase-I reactions 
such as aromatic hydroxylation, dehydrogenation, O-, and N- 
dealkylation [31, 44, 45]. 
A special focus of drug metabolism studies is the detection of 
reactive metabolites which often cause severe side effects. A high 
proportion of drugs involved in idiosyncratic toxicity are capable of 
forming reactive metabolic intermediates [46-48]. The majority of 
these intermediates are formed  after the oxidation of the parent 
compound to an electrophilic intermediate, which subsequently can 
react with nucleophilic groups in cellular biomacromolecules such 
as lipids, proteins and DNA [48-50]. These reactive metabolites can 
be generated by metabolic phase-I reactions (oxidation, reduction), 
e.g. catalyzed by cytochrome P450s (CYP), flavin monooxygenases 
(FMO), and peroxidases and also by phase-II reactions (conjuga- 
tion), e.g. catalyzed by UDP glucuronyltransferases (UGT) or sul- 
fotransferases (SULT) [48]. 
The short lifetimes of electrophilic reactive intermediates, have 
boosted the development of analytical strategies mainly based in in 
situ trapping. Several approaches using “on-line metabolite genera- 
tion” have been described to increase throughput in early drug me- 
tabolism studies. An instrumental approach is the use of on-line 
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Fig. (5). Interaction of electrophilic intermediates generated during tamoxifen metabolism with gluthatione (GSH). 
 
electrochemistry–mass spectrometry (EC–MS) to mimic cyto- 
chrome P450-catalyzed reactions [43, 51-53]. The on-line coupling 
of EC with LC-MS has evolved as a powerful tool for the elucida- 
tion and study of drug metabolism reactions in recent years [54-56]. 
Oxidative metabolism reactions are simulated  electrochemically 
and metabolites are separated with HPLC and identified with MS. 
Although standard in vivo and in vitro approaches, such as the use 
of liver microsomes, can certainly not be replaced by EC, the purely 
instrumental technique has found its application in several comple- 
mentary issues [56]. 
Damage to DNA may result in critical disturbances in the cell 
life and have serious impacts on the human’s health. Development 
and improvement of analytical techniques capable of rapid and 
sensitive detection  of various types of DNA damage and  DNA 
damaging agents is therefore important. Electrochemical analysis of 
DNA offers a number of approaches in DNA damage detection as 
well as in sensing of DNA damaging agents in the environment, in 
food, in clinical samples, etc. Several reviews are available on elec- 
trochemical biosensors and particularly on applications of DNA 
modified electrodes as sensors for the detection of drugs or poten- 
tial DNA-damaging agents [57-62]. 
Analysis of Tamoxifen and Metabolites 
Regarding tamoxifen pharmaceutical interest as a nonsteroidal 
antiestrogen and despite its elevated risk of endometrial carcinoma, 
whether being a consequence of a DNA-damaging (genotoxic) or 
non-genotoxic mechanism remains obscure, the potential offered by 
electrochemical methods to highlight some of these uncertain issues 
have been poorly explored. In fact, very few studies based on elec- 
trochemistry have been performed and reported in the literature for 
tamoxifen and its metabolites. The majority of the data published in 
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Fig. (6). Activation of 4-hydroxytamoxifen (4-OHTAM) and subsequent formation of dimerization products. 
 
literature was attained in view of the development of simple and 
rapid electroanalytical methods for the determination of tamoxifen. 
The polarographic and voltammetric behaviour of tamoxifen 
and other triphenylethene derivatives have been evaluated and the 
redox properties were used for its determination in pure form and in 
pharmaceutical tablets [63]. The observed polarographic reduction 
of tamoxifen was assigned to the cleavage of the double ethylenic 
bond involving the transfer of two electron and two protons per 
molecule of reactant (Fig. 8). On the other hand, the anodic signal 
was attributed to the cyclization reaction to form the corresponding 
phenanthrene derivative (Fig. 8). A similar mechanism was pro- 
posed for the oxidation of tamoxifen at various electrodes [64, 65]. 
Although the data found in literature concerning the oxidative 
mechanism of tamoxifen is coincident, and follows the generally 
accepted mechanism proposed for phenylethenes derivatives oxida- 
tion [66, 67] there are some remaining issues that need to be pur- 
sued. In fact, in addition to the double ethylenic bond, tamoxifen’s 
molecular structure includes other functional groups that could also 
undergo oxidative reactions (Fig. 1), namely an oxygen aromatic 
ether and an aliphatic tertiary amine. Compounds containing these 
organic moieties have been described in literature as being electro- 
active and  presenting anodic waves at potentials similar to  that 
found for tamoxifen (ca. 1.0 V) [68-71]. Furthermore, as mentioned 
previously tamoxifen metabolism in humans comprises mainly N- 
desalkylation of the aminoethoxy side chain. The major oxidative 
metabolite of tamoxifen found in human plasma is N-desmethyl 
tamoxifen (N-demTAM). 
The oxidation of tamoxifen at a glassy carbon flow detector was 
exploited for its amperometric chromatographic monitoring in cell 
culture medium [72]. The absolute detection limit obtained was 100 
pg for tamoxifen at a sensitivity of 1 nA/V. 
A highly sensitive adsorptive chronopotentiometric stripping 
voltammetric method was proposed for the analysis of trace ta- 
moxifen at a glassy carbon electrode [64]. The adsorptive stripping 
response was evaluated with respect to different variables and the 
developed method was successfully used for tamoxifen 
determination in  urine,  with a  detection  limit  of  4  10
-10   
M  after   
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4  min preconcentration. 
A single-sweep voltammetric method was proposed for the 
determination of tamoxifen [65] in pharmaceutical dosage samples. 
The described methodology took advantage of both the higher ca- 
pacity for accumulation of carbon paste electrode toward tamoxifen 
and the rapidity of single-sweep voltammetry. The proposed 
method, characterized by its rapidity and higher sensitivity, was 
evaluated by analyzing tamoxifen citrate tablets, and yielded a de- 
tection limit of 1.0  10
-10 
M without any preconcentration. 
Recently, an ultrasensitive flow-injection electrochemical 
method was proposed for the determination of tamoxifen in urine, 
plasma and pharmaceutical preparations [73]. The reported meth- 
odology describes a novel, sensitive and widely applicable fast 
Fourier transform (FFT) square wave voltammetry (SWV) using a 
gold microelectrode in flow-injection system. FFT–SWV was dem- 
onstrated to provide sensitive detection based on oxidation of the 
electrode surface. Under optimum conditions at flow-injection sys- 
tem, a detection limit of 3.0  10 
12 
M was obtained for tamoxifen. 
Future Prospects 
Tamoxifen remains a frontline treatment for hormone-res- 
ponsive breast cancer despite its use being associated with an ele- 
vated risk of developing endometrial carcinoma. The mechanisms 
underlying the induction of endometrial tumors by tamoxifen have 
yet to be established, although both the genotoxic and the hormonal 
properties of the drug have been implicated. 
As many drugs, tamoxifen is biotransformed to pharmacologi- 
cally active metabolites that can significantly contribute to the 
overall pharmacological or adverse effects of the drug. For the most 
part, the pharmacological actions attributed to active metabolites 
are similar to those of the parent. However,  active  metabolites 
could also mediate therapeutic effects that are synergistic or even 
the reverse of the pharmacological action of the parent drug. There- 
fore, to fully understand the mechanism of action of a drug, it is 
imperative to recognize the role of active metabolites. 
Recently, researchers have utilized an electrochemistry-based 
approach to answer many questions about a compound’s metabolic 
behaviour [31, 43, 52, 53]. Electrochemical systems take advantage 
of the relationship between oxidation/reduction chemistry and 
CYP450-mediated oxidative drug metabolism (Phase I metabolism) 
to provide a wide variety of information on metabolic characteris- 
tics. Even though it is still not possible to simulate the complete 
spectrum of CYP mediated metabolic  reactions adequately,  and 
differences between the electrochemically and enzymatically gen- 
erated metabolites occur, this technique has already shown its po- 
tential as a tool that is complementary to existing techniques [31, 
43, 53]. 
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The development of new detection methods based on electro- 
chemistry are particularly interesting because their sensitivity and 
the opportunity to miniaturize the technology [75, 76]. The attrac- 
tive properties of electrochemical devices are extremely promising 
for improving the efficiency of diagnostic testing and therapy moni- 
toring of tamoxifen. Nevertheless, some new studies on the volt- 
ammetric behaviour of tamoxifen should be accomplished in order 
to clarify its oxidative mechanism. 
The development of electrochemical DNA-biosensors for the 
study of tamoxifen could open a wide perspective using particularly 
sensitive and selective methods for the detection of specific interac- 
tions. This biosensor would enable pre-concentration of tamoxifen 
onto the sensor surface and in situ electrochemical generation of 
radical intermediates, which can cause damage to the DNA immo- 
bilized on the electrode surface and can be detected electrochemi- 
cally. Voltammetric methods can therefore contribute to elucidation 
of the mechanism through which DNA is oxidatively damaged by 
tamoxifen and its metabolites. 
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